Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Comparative analysis of survival, treatment, cost and resource use among patients newly diagnosed with brain metastasis by initial primary cancer.

Ray S, Dacosta-Byfield S, Ganguli A, Bonthapally V, Teitelbaum A.

J Neurooncol. 2013 Aug;114(1):117-25. doi: 10.1007/s11060-013-1160-0. Epub 2013 May 23.

PMID:
23700325
2.

Epidemiology and economic burden of brain metastases among patients with primary breast cancer: results from a US claims data analysis.

Pelletier EM, Shim B, Goodman S, Amonkar MM.

Breast Cancer Res Treat. 2008 Mar;108(2):297-305. Epub 2007 Jun 19.

PMID:
17577662
3.

Long-term survival with metastatic cancer to the brain.

Hall WA, Djalilian HR, Nussbaum ES, Cho KH.

Med Oncol. 2000 Nov;17(4):279-86.

PMID:
11114706
4.

Patient survival and healthcare utilization costs after diagnosis of triple-negative breast cancer in a United States managed care cancer registry.

Baser O, Wei W, Henk HJ, Teitelbaum A, Xie L.

Curr Med Res Opin. 2012 Mar;28(3):419-28. doi: 10.1185/03007995.2011.628649. Epub 2012 Feb 24.

PMID:
22364568
5.

Identification of prognostic factors in patients with brain metastases: a review of 1292 patients.

Lagerwaard FJ, Levendag PC, Nowak PJ, Eijkenboom WM, Hanssens PE, Schmitz PI.

Int J Radiat Oncol Biol Phys. 1999 Mar 1;43(4):795-803. Review.

PMID:
10098435
6.

The burden of metastatic melanoma: treatment patterns, healthcare use (utilization), and costs.

Reyes C, DaCosta Byfield S, Linke R, Satram-Hoang S, Teitelbaum AH.

Melanoma Res. 2013 Apr;23(2):159-66. doi: 10.1097/CMR.0b013e32835e58d6.

PMID:
23370422
7.

Direct economic burden of high-risk and metastatic melanoma in the elderly: evidence from the SEER-Medicare linked database.

Davis KL, Mitra D, Kotapati S, Ibrahim R, Wolchok JD.

Appl Health Econ Health Policy. 2009;7(1):31-41. doi: 10.2165/00148365-200907010-00004.

PMID:
19558193
8.

Economic burden of brain metastases among patients with metastatic melanoma in a USA managed care population.

Vekeman F, Cloutier M, Yermakov S, Amonkar MM, Arondekar B, Duh MS.

Melanoma Res. 2014 Dec;24(6):602-10. doi: 10.1097/CMR.0000000000000097.

PMID:
24926818
9.

Impact of metastatic colorectal cancer stage and number of treatment courses on patient health care costs and utilization.

Chastek B, Kulakodlu M, Valluri S, Seal B.

Postgrad Med. 2013 Mar;125(2):73-82. doi: 10.3810/pgm.2013.03.2642.

PMID:
23816773
10.

Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System.

Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE.

J Clin Oncol. 2004 Jul 15;22(14):2865-72.

PMID:
15254054
11.

Utilization and cost of health care services associated with primary malignant brain tumors in the United States.

Kutikova L, Bowman L, Chang S, Long SR, Thornton DE, Crown WH.

J Neurooncol. 2007 Jan;81(1):61-5. Epub 2006 Jun 14.

PMID:
16773215
12.

Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma.

Schouten LJ, Rutten J, Huveneers HA, Twijnstra A.

Cancer. 2002 May 15;94(10):2698-705.

13.

Treatment outcome for patients with primary nonsmall-cell lung cancer and synchronous brain metastasis.

Chidel MA, Suh JH, Greskovich JF, Kupelian PA, Barnett GH.

Radiat Oncol Investig. 1999;7(5):313-9.

PMID:
10580901
14.

Stereotactic radiosurgery for brain metastases: comparison of lung carcinoma vs. non-lung tumors.

Williams J, Enger C, Wharam M, Tsai D, Brem H.

J Neurooncol. 1998 Mar;37(1):79-85.

PMID:
9525842
15.

Prognostic factors for survival in patients treated with stereotactic radiosurgery for recurrent brain metastases after prior whole brain radiotherapy.

Caballero JA, Sneed PK, Lamborn KR, Ma L, Denduluri S, Nakamura JL, Barani IJ, McDermott MW.

Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):303-9. doi: 10.1016/j.ijrobp.2011.06.1987. Epub 2011 Nov 11.

PMID:
22079723
16.

Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.

Pelletier EM, Ogale S, Yu E, Brunetta P, Garg J.

Clin Ther. 2009 Nov;31(11):2653-64. doi: 10.1016/j.clinthera.2009.11.032.

PMID:
20110008
17.

Prognosis of patients treated for intracranial metastases with whole-brain irradiation.

Sundström JT, Minn H, Lertola KK, Nordman E.

Ann Med. 1998 Jun;30(3):296-9.

PMID:
9677016
18.

Nonsmall cell lung cancer presenting with synchronous solitary brain metastasis.

Hu C, Chang EL, Hassenbusch SJ 3rd, Allen PK, Woo SY, Mahajan A, Komaki R, Liao Z.

Cancer. 2006 May 1;106(9):1998-2004.

19.

[Survival after cutaneous metastasis: a study of 200 cases].

Schoenlaub P, Sarraux A, Grosshans E, Heid E, Cribier B.

Ann Dermatol Venereol. 2001 Dec;128(12):1310-5. French.

20.

The economic burden of brain metastasis among lung cancer patients in the United States.

Guérin A, Sasane M, Dea K, Zhang J, Culver K, Nitulescu R, Wu EQ, Macalalad AR.

J Med Econ. 2016;19(5):526-36. doi: 10.3111/13696998.2016.1138962. Epub 2016 Jan 22.

PMID:
26735844

Supplemental Content

Support Center